The full content of Annals is available to subscribers

Subscribe/Learn More  >
Original Research |

Treatment of Angioimmunoblastic Lymphadenopathy (AILD)-Type T-Cell Lymphoma Using Prednisone with or without the COPBLAM/IMVP-16 Regimen: A Multicenter Study

Wolfgang Siegert, MD; Alexander Agthe; Henrik Griesser, MD; Rainer Schwerdtfeger, MD; Günter Brittinger, MD; Marianne Engelhard, MD; Rolf Kuse, MD; Markus Tiemann, MD; Karl Lennert, MD; and Dieter Huhn, MD
[+] Article, Author, and Disclosure Information

Requests for Reprints: Wolfgang Siegert, MD, Freie Universität Berlin, Universitätsklinikum Rudolf Virchow, Standort Charlottenburg, Spandauer Damm 130, 1000 Berlin 19, Germany.

Current Author Addresses: Drs. Siegert, Huhn, and Schwerdtfeger and Mr. Agthe: Freie Universität Berlin, Universitätsklinikum Rudolf Virchow, Standort Charlottenburg, Spandauer Damm 130, 1000 Berlin 19, Germany.

Drs. Lennert, Griesser, and Tiemann: Universität Kiel, Niemannsweg 11, D-2300 Kiel 1, Germany.

Drs. Brittinger and Engelhard: Medizinische Klinik und Poliklinik, Universität GHS, Hufelandstrasse 55, 4300 Essen 1, Germany. Dr. Kuse: Allgemeines Krankenhaus St. Georg, Lohmühlenstrasse 5, 2000 Hamburg 1, Germany.

Kiel Lymphoma Study Group

©1992 American College of PhysiciansAmerican College of Physicians

Ann Intern Med. 1992;117(5):364-370. doi:10.7326/0003-4819-117-5-364
Text Size: A A A

Objective: To describe the clinical course of patients with angioimmunoblastic lymphadenopathy (AILD)-type lymphoma with a sequential treatment with prednisone and COPBLAM/IMVP-16.

Design: A multicenter, prospective, nonrandomized trial.

Setting: University medical centers and community hospitals.

Patients: Sixty-seven patients were registered, 28 were excluded, and 39 patients were evaluable for response (median age, 59 years; range, 25 to 82 years) (stages I and II, 10%; stages III and IV, 90%; B symptoms, 74%).

Measurements: Response, survival, and relapse.

Intervention: Patients initially received prednisone and no further treatment if a complete remission was achieved. Relapsing or refractory patients were treated with COPBLAM/IMVP-16. Patients with life-threatening tumor progression or extension received COPBLAM/IMVP-16 initially. Treatments were chosen in accordance with tumor extension and response to prednisone. Treatment modalities were not compared.

Results: Twenty-eight patients received primary prednisone, 18 received secondary prednisone, and 11 received primary chemotherapy. The complete response rates (with 95% Cls) were 29% (Cl, 12% to 46%), 56% (Cl, 33% to 79%), and 64% (Cl, 36% to 92%), respectively. The median observation time of surviving patients was 28 months (range, 7 to 53). The median overall survival time was 15 months. The probabilities (with 95% Cls) of overall survival, event-free survival, and relapse at 36 months were 40.5% (Cl, 24% to 56%), 32.3% (Cl, 17% to 47%), and 34.6% (Cl, 14% to 56%), respectively. At the time of evaluation, 22 of 39 patients had died, 7 of noninfectious complications and 14 of infections.

Conclusions: Prednisone with or without COPBLAM/IMVP-16 treatment in AILD-type lymphoma leads to complete remissions in about half of the patients and in long-term, disease-free survival for one third.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $42.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Journal Club
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.